Hanmi Pharm is trading at 353,000 KRW as of 12:30 PM on the 27th, up 7.13% from the previous day. The trading volume is 313,820 shares, which is 47.94% of the previous day's volume. Hanmi Pharm is known as a pharmaceutical company specializing in the production of prescription drugs.
On November 27, Hyungsoo Kim, a researcher at Cape Investment & Securities, stated, "A research and development-focused pharmaceutical company that has proven its new drug development capabilities through multiple technology exports. Although there is some disappointment due to the termination of technology export contracts, attention should be paid to the new drug development know-how acquired by the company during that period. A global new drug launch is expected in 2021. Profitability has deteriorated due to the reflection of joint development costs with Sanofi, whose contract was terminated. A global new drug launch is expected in 2021." He set Hanmi Pharm's target price at 400,000 KRW.
Over the past five days, individual investors have net purchased 26,207 shares of Hanmi Pharm, while foreigners and institutions have net sold 40,245 shares and net purchased 20,961 shares, respectively.
※Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an article auto-generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
